These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 10326964)
1. Human lens cholesterol concentrations in patients who used lovastatin or simvastatin. Mitchell J; Cenedella RJ Arch Ophthalmol; 1999 May; 117(5):653-7. PubMed ID: 10326964 [TBL] [Abstract][Full Text] [Related]
2. Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens. de Vries AC; Vermeer MA; Bloemendal H; Cohen LH Invest Ophthalmol Vis Sci; 1993 Feb; 34(2):377-84. PubMed ID: 8440592 [TBL] [Abstract][Full Text] [Related]
3. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. Pappu AS; Bacon SP; Illingworth DR J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170 [TBL] [Abstract][Full Text] [Related]
4. Concentration and distribution of ubiquinone (coenzyme Q), the endogenous lipid antioxidant, in the rat lens: effect of treatment with simvastatin. Cenedella RJ; Neely AR; Sexton P Mol Vis; 2005 Aug; 11():594-602. PubMed ID: 16110301 [TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
7. Lovastatin and simvastatin prevention studies. Jones PH Am J Cardiol; 1990 Sep; 66(8):39B-43B. PubMed ID: 2206035 [TBL] [Abstract][Full Text] [Related]
8. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin. De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554 [TBL] [Abstract][Full Text] [Related]
9. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR; Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Slater EE; MacDonald JS Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125 [TBL] [Abstract][Full Text] [Related]
12. Amounts of phospholipids and cholesterol in lipid domains formed in intact lens membranes: Methodology development and its application to studies of porcine lens membranes. Raguz M; Mainali L; O'Brien WJ; Subczynski WK Exp Eye Res; 2015 Nov; 140():179-186. PubMed ID: 26384651 [TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Farnier M; Bonnefous F; Debbas N; Irvine A Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of medium-term treatment with simvastatin in primary hypercholesterolaemia. Marnini P; Colombo F; Cattaneo R; Geroli L; Venco A Int J Clin Pharmacol Res; 1992; 12(2):65-70. PubMed ID: 1428300 [TBL] [Abstract][Full Text] [Related]
15. [Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia]. Darioli R; Bovet P; Brunner HR; Bercher L Schweiz Med Wochenschr; 1990 Jan; 120(4):85-91. PubMed ID: 2305221 [TBL] [Abstract][Full Text] [Related]
16. Studies on the distribution of cholesterol, phospholipid, and protein in the human and bovine lens. Borchman D; Delamere NA; McCauley LA; Paterson CA Lens Eye Toxic Res; 1989; 6(4):703-24. PubMed ID: 2487279 [TBL] [Abstract][Full Text] [Related]
17. Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug. Cheetham TC; Chan J; Benson V; Richmond C; Levin E; Campen D Am J Manag Care; 2005 Sep; 11(9):546-52. PubMed ID: 16159044 [TBL] [Abstract][Full Text] [Related]
18. Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial. Leclercq V; Harvengt C Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):76-81. PubMed ID: 2921098 [TBL] [Abstract][Full Text] [Related]
19. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia. Frohlich J; Brun LD; Blank D; Campeau L; Crockford P; Curnew G; Dafoe W; Davignon J; Dufour R; Emery G Can J Cardiol; 1993 Jun; 9(5):405-12. PubMed ID: 8348392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]